ROR2 Targeting for ALK+ Lymphoma Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Anaplastic large cell lymphoma (ALCL) ALK+ tumors exhibit high relapse rates and resistance to chemotherapy, particularly with mechanisms of resistance observed against ALK inhibitors, necessitating a novel therapeutic approach.
Innovation Solution
The use of CRISPR/Cas9 system to induce NPM1-ALK translocation in primary human T-cells, leading to increased survival and tumor formation in immunodeficient mice, identifying ROR2 as progressively upregulated during tumorigenesis, which is correlated with NPM-ALK expression and increased in resistant cells to crizotinib, suggesting ROR2 as a target for specific therapies such as inhibitors, monoclonal antibodies, and CAR-T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy or ALK inhibitors are used to treat ALCL ALK+ tumors, then initial response rates are high, but resistance develops and relapse rates increase
Solution Approach 1:
The patent extracts and targets the specific molecular mechanism (ROR2 signaling pathway) that drives tumor survival and resistance in ALCL ALK+ tumors. By isolating this critical dependency, the invention enables selective inhibition of the resistance mechanism while preserving sensitivity to ALK inhibitors, thereby resolving the contradiction between initial treatment efficacy and subsequent resistance development
Solution Approach 2:
The patent combines ALK inhibitors with ROR2 inhibitors in a composite therapeutic approach. This combination therapy addresses both the primary driver (ALK fusion) and the resistance/survival mechanism (ROR2 signaling), thereby maintaining treatment efficacy while preventing the development of resistance that occurs with single-agent therapy
2Reliability
If high-dose chemotherapy is administered to improve survival rates, then response rates increase, but toxicity and treatment complexity increase
Solution Approach 1:
The patent replaces the mechanical/toxic approach of high-dose chemotherapy with a molecularly targeted approach using ROR2 inhibitors. This substitution achieves comparable or superior therapeutic efficacy by targeting the specific molecular dependency (ROR2 signaling) in ALCL ALK+ tumors, thereby improving survival without the excessive toxicity and complexity associated with high-dose chemotherapy protocols
3Reliability
If ALK inhibitors are used to target the NPM1-ALK fusion, then tumor growth is inhibited initially, but resistance mechanisms develop
Solution Approach 1:
The patent applies preliminary action by inhibiting ROR2 signaling in combination with ALK inhibitors from the outset of treatment. This preemptive dual-targeting approach prevents the development of resistance mechanisms before they can emerge, thereby extending the duration of therapeutic response beyond what is achievable with ALK inhibitors alone
Solution Approach 2:
The patent introduces ROR2 inhibition as an intermediary mechanism that blocks the survival signaling pathways activated by the NPM1-ALK fusion. By targeting this intermediate survival signal (ROR2) in addition to the primary driver (ALK), the invention extends the duration of response and prevents resistance development that occurs with direct ALK inhibition alone
Data Source
AI summary
Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphoma affects lymph nodes and extra-nodal sites with characteristic skin lesions. Approximatively half of the tumors express the NPM1-ALK fusion from the translocation t(2;5)(p23;q32). In the present study, the inventors identify ROR2 as progressively up regulated thought tumorigenesis. Patient samples show a significantly high ROR2 expression (transcriptomic data) as well as a strong ROR2 protein expression (IHC) with some tumors displaying a clear membrane signal. ROR2 mRNA expression level is also positively correlated to NPM-ALK expression level in tumor cells and is not expressed in normal T cells. In addition, ROR2 protein level is significantly increased in resistant cells to the ALK inhibitor, crizotinib, used in clinical trials for children with refractory tumors. This result opens the road to ROR2 specific therapies: ROR2 inhibitors, monoclonal antibodies therapies or even ROR2 specific CAR cells, including for ALCL ALK(+) resistant tumors.